

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



7 March 2022

Graham McLean Appointed as Non-Executive Director of Universal Biosensors

Universal Biosensors, Inc. (ASX Code: UBI) (UBI) is pleased to announce the appointment of Mr. Graham McLean as Non-Executive Director.

Mr. McLean has more than 20 years' business and corporate governance experience and is an experienced senior executive leader with extensive service in the medical technology industry in Australia, Asia and US, most recently with Stryker Corporation ('Stryker') as President Asia Pacific. Whilst at Stryker, Mr. McLean led a transformation of Asia Pacific to renew growth in Japan and China and led an accelerated growth strategy for Australia/New Zealand. Prior to his time with Stryker, Mr. McLean was Lion Nathan's Finance Director International/Business Development and Director Group Risk Assurance & Audit.

Since 2021 Mr. McLean has served as an Independent Director and Chairman of the Audit and Risk Committee at both Suicide Prevention Australia and recently CleanSpace Holdings Ltd (ASX Code: CSX) and also is an Advisor to Bain & Company. He has also previously served on industry boards in Australia (Medical Technology Association of Australia), Japan (American Medical Devices & Diagnostics Manufacturers Association) and Asia Pacific where he was Vice Chairman of the Asia Pacific Medical Technology Association.

Mr. McLean has:

- Delivered a successful recovery for Stryker's business in Japan;
- Rebuilt the Stryker China business with an intensive investment and talent plan;
- Extended market leadership and share gains in Australia/New Zealand;
- Successfully restructured Lion Nathan's \$100M international operations to set springboard for further international growth; and
- Introduced risk management systems to Lion Nathan Board, which enabled key strategic and operational decisions in China, wine and non-core businesses.

Mr. McLean is a Graduate of the Australian Institute of Company Directors and a Qualified Accountant (both CIMA and CPA). He holds a Bachelor of Science, Geography (Honours) (Durham University) and has completed 3 Executive Leadership Programmes (Harvard Business School).

Regarding his appointment, Mr. McLean said: "I am excited to be joining the UBI Board during what is a high-growth period for the Company. The innovative product development pipeline and

recent commercial launches are placing the Company in a strong position to pursue valuable business opportunities”.

UBI’s Non-Executive Chairman, Mr. Craig Coleman said: “We look forward to welcoming Graham to the Board. As part of its ongoing succession planning, the Board is committed to ensuring a strong cohort and mix of skills, knowledge and experience. Graham has an accomplished non-executive and executive career and his broad experience will further strengthen the Board and complement the skills and expertise of current Board members. Specifically, his prior experience in the global medical technology industry, as well as the beverage industry is well aligned to UBI’s operations”.

Enquiries:

Craig Coleman
Chairman
+61 (0) 481 010 348

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

**About Universal Biosensors**

For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), food and drink and agriculture.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.